

Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2024) [Under Japanese GAAP]

May 10, 2024
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.

Code number: 4569

Web site: <https://www.kyorin-pharm.co.jp/>

Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer

Contact: Sakurou Banba, Director, Finance & Accounting

TEL 03-6374-9704

Scheduled date for Ordinary General Meeting of Shareholders: June 21, 2024

Scheduled date for starting dividend payment: June 5, 2024

Scheduled date for submitting securities report: June 24, 2024

(Amounts rounded down to the nearest million yen)

1. Consolidated Results for the Fiscal Year Ended March 31, 2024 (From April 1, 2023, to March 31, 2024)

(1) Consolidated Operating Results

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Fiscal year ended March 31, 2024	119,532	5.5	6,013	17.4	6,602	13.3	5,322	12.7
March 31, 2023	113,270	7.3	5,123	2.3	5,827	4.6	4,723	20.1

(Note) Comprehensive income: For the fiscal year ended March 31, 2024: 7,949 million yen (99.4%),
For the fiscal year ended March 31, 2023: 3,986 million yen (10.0%)

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
	Yen	Yen	%	%	%
Fiscal year ended March 31, 2024	92.74	—	4.2	3.7	5.0
March 31, 2023	82.44	—	3.8	3.3	4.5

(Note) Share of loss(profit) of entities accounted for using equity method: For the fiscal year ended March 31, 2024: —12 million yen,
For the fiscal year ended March 31, 2023: —0 million yen

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	yen
As of March 31, 2024	177,679	130,783	73.6	2,276.52
March 31, 2023	176,045	125,461	71.3	2,189.40

(Note) Equity: As of March 31, 2024: 130,783 million yen, As of March 31, 2023: 125,461 million yen

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of year
	Million yen	Million yen	Million yen	Million yen
Fiscal year ended March 2024	1,549	—3,187	—3,347	13,886
March 2023	2,008	—6,275	—3,363	18,816

2. Dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
(Record date)	Yen	Yen	Yen	Yen	Yen	Million Yen	%	%
Fiscal year ended March 31, 2023	—	20.00	—	32.00	52.00	3,023	64.0	2.4
Fiscal year ended March 31, 2024	—	20.00	—	32.00	52.00	3,023	56.8	2.3
Fiscal year ending March 31, 2025 (Forecast)	—	20.00	—	32.00	52.00		60.5	

3. Forecast of Consolidated for the Year Ending March 31, 2025 (From April 1, 2024, to March 31, 2025)

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	56,900	3.6	1,000	-12.6	1,300	-6.3	900	-48.8	15.67
Full year	123,400	3.2	6,500	8.1	6,900	4.5	5,000	-6.1	87.03

4. Other

(1) Changes in major subsidiaries during the period

(Change of specified subsidiaries associated with a change of the scope of consolidation): Yes

Newly included: None

Excluded: 1 company (The former Kyorin Pharmaceutical Co., Ltd.)

(2) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes due to mandatory changes of accounting standards : None

(ii) Changes other than i) : None

(iii) Changes in accounting estimates : Yes

(iv) Restatements : None

(3) Number of shares issued (common stock)

(i) Number of shares issued and outstanding at the end of the fiscal year (including treasury stock)

Fiscal year ended March 31 2024: 64,607,936 shares,

Fiscal year ended March 31 2023: 64,607,936 shares

(ii) Number of shares of treasury stock at the end of the fiscal year

Fiscal year ended March 31 2024: 7,159,151 shares,

Fiscal year ended March 31 2023: 7,304,066 shares

(iii) Averaged number of shares of during the period

Fiscal year ended March 31 2024: 57,389,377 shares,

Fiscal year ended March 31 2023: 57,303,071 shares

* This financial report is not subject to audit procedures by Certified Public Accountants or audit firm.

* Explanations about the appropriate use of the business forecasts and other noteworthy points.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

Supplementary materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.